{"id":"W2902378590","doi":"10.1002/cncr.31891","title":"Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"Ignyta; Chugai Pharmaceutical; Novartis Pharma; Genentech; Ono Pharmaceutical; Loxo Oncology; Astellas Pharma; Yuhan; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Clovis Oncology; Ariad Pharmaceuticals; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; T790M; Osimertinib; Internal medicine; Discontinuation; Lung cancer; Clinical endpoint; Hazard ratio; Confidence interval; Gastroenterology; Surgery; Oncology; Cancer; Clinical trial; Epidermal growth factor receptor; Gefitinib; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03549641,0.002034808,0.007227859,0.002559936,0.0005875144,0.003235339,0.0008829588,0.001628883,0.001487485],"category_scores_gemma":[0.0215068,0.0011397,0.02066145,0.003221631,0.0004731822,0.001881956,0.001446849,0.001305134,0.0002643671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001265903,"about_ca_system_score_gemma":0.001028497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009452336,"about_ca_topic_score_gemma":0.002737568,"domain_scores_codex":[0.9808818,0.01093791,0.003079058,0.002668441,0.001788387,0.0006444922],"domain_scores_gemma":[0.9738498,0.01111093,0.01018897,0.002576729,0.001743216,0.0005303153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.08708055,0.0002255385,0.1678286,0.007313114,0.7021618,0.0003825058,0.0002328803,0.001792811,0.002383279,0.00007704644,0.001583594,0.02893825],"study_design_scores_gemma":[0.0132324,0.00870403,0.3293304,0.001268647,0.6389058,0.0008654255,0.000212653,0.00156847,0.001015343,0.0003477032,0.004388901,0.0001602118],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6012218,0.3849396,0.004128317,0.0007417812,0.0003947526,0.0007378415,0.006223434,0.0001182185,0.001494253],"genre_scores_gemma":[0.9799806,0.01358303,0.0008424664,0.0005075272,0.0003309561,0.0003545092,0.004067911,0.00004162855,0.0002912127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03549641,"threshold_uncertainty_score":0.1877251,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01175999927836135,"score_gpt":0.3536241179805094,"score_spread":0.3418641187021481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}